medigraphic.com
ISSN 1561-2996 (Digital)
ISSN 0864-0289 (Impreso)

2015, Número 4

<< Anterior Siguiente >>

Rev Cubana Hematol Inmunol Hemoter 2015; 31 (4)


Inducción de células T reguladoras por estatinas: alternativa terapéutica para el control del asma extrínseca

Blanquiceth MY, Rodríguez PAL, Montoya GCJ, Velilla HPA

Idioma: Español
Referencias bibliográficas: 54
Paginas: 393-404
Archivo PDF: 223.14 Kb.


RESUMEN

El asma bronquial extrínseca se origina por una reacción inmunológica de hipersensibilidad tipo I, desencadenada principalmente por alérgenos ambientales. Clásicamente, la respuesta inmune mediada por células T CD4+ con perfil Th2 determina las principales características de esta enfermedad, con la infiltración de eosinófilos y basófilos que median la inflamación crónica de las vías aéreas. Se ha observado que las células T reguladoras pueden actuar como moduladores endógenos durante los procesos asmáticos, controlando la exacerbación de las crisis y disminuyendo el daño tisular. Aunque los glucocorticoides son el principal tratamiento para el asma, solo alivian temporalmente los síntomas y se asocian con efectos adversos y aparición de resistencia, lo cual ha incentivado el desarrollo de alternativas terapéuticas que modulen la respuesta inmune y controlen la inflamación crónica. Recientemente, se ha postulado que las estatinas podrían ser una alternativa promisoria para disminuir la respuesta inflamatoria y disminuir la morbilidad asociada a esta enfermedad, debido a su gran potencial inmunomodulador, entre los que se destaca la inducción de células T reguladoras.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Global Asthma Network. The Global Asthma Report. 2014. Auckland, New Zealand 2014.

  2. Río-Navarro Blanca E, Hidalgo-Castro EM, Sienra-Monge Juan JL. Asma. Bol. Med. Hosp. Infant. Mex. 2009 Feb;66(1):3-33.

  3. Madore AM, Laprise C. Immunological and genetic aspects of asthma and allergy. J Asthma Allergy. 2010;3:107-121.

  4. Bateman ED, Hurd SS, Barnes PJ. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1):143-178.

  5. Kim YM, Kim YS, Jeon SG, Kim YK. Immunopathogenesis of allergic asthma: more than the th2 hypothesis. Allergy Asthma Immunol Res. 2013;5(4):189-196.

  6. Urboniene D, Babusyte A, Lötvall J, Sakalauskas R, Sitkauskiene B. Distribution of γδ and other T-lymphocyte subsets in patients with chronic obstructive pulmonary disease and asthma. Respir Med. 2013;107(3):413-423.

  7. Murdoch JR, Lloyd CM. Chronic inflammation and asthma. Mutat Res. 2010;690(1-2):24-39.

  8. Burchell JT, Strickland DH, Stumbles PA. The role of dendritic cells and regulatory T cells in the regulation of allergic asthma. Pharmacol Ther. 2010;125(1):1-10.

  9. Durham A, Adcock IM, Tliba O. Steroid resistance in severe asthma: current mechanisms and future treatment. Curr Pharm Des. 2011;17(7):674-684.

  10. Liu JN, Suh DH, Yang EM, Lee SI, Park HS, Shin YS. Attenuation of airway inflammation by simvastatin and the implications for asthma treatment: is the jury still out? Exp Mol Med. 2014;46:e113.

  11. Yoo Y, Perzanowski MS. Allergic sensitization and the environment: latest update. Curr Allergy Asthma Rep. 2014;14(10):465.

  12. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol. 2008;8(3):218-230.

  13. Hew M, Chung KF. Corticosteroid insensitivity in severe asthma: significance, mechanisms and aetiology. Intern Med J. 2010;40(5):323-334.

  14. Abbas AK, Benoist C, Bluestone JA, et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol. 2013;14(4):307-308.

  15. González JL, Duque V, Velásquez-Lopera M. FOXP3: Controlador maestro de la generación y función de las células reguladoras naturales. Inmulogía;2010;29:74-84.

  16. Yadav M, Stephan S, Bluestone JA. Peripherally induced tregs - role in immune homeostasis and autoimmunity. Front Immunol. 2013;4:232.

  17. Haque M, Fino K, Lei F, Xiong X, Song J. Utilizing regulatory T cells against rheumatoid arthritis. Front Oncol. 2014;4:209.

  18. Kearley J, Barker JE, Robinson DS, Lloyd CM. Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent. J Exp Med. 2005;202(11):1539-1547.

  19. Boudousquié C, Pellaton C, Barbier N, Spertini F. CD4+CD25+ T cell depletion impairs tolerance induction in a murine model of asthma. Clin Exp Allergy. 2009;39(9):1415-1426.

  20. Whitehead GS, Wilson RH, Nakano K, Burch LH, Nakano H, Cook DN. IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease. J Allergy Clin Immunol. 2012;129(1):207-215.

  21. Gri G, Piconese S, Frossi B, et al. CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity. Nov. 2008;29(5):771-781.

  22. McGee HS, Yagita H, Shao Z, Agrawal DK. Programmed Death-1 antibody blocks therapeutic effects of T-regulatory cells in cockroach antigen-induced allergic asthma. Am J Respir Cell Mol Biol. Oct. 2010;43(4):432-442.

  23. Zhang F, Huang G, Hu B, Song Y, Shi Y. Induction of immune tolerance in asthmatic mice by vaccination with DNA encoding an allergen-cytotoxic T lymphocyte-associated antigen 4 combination. Clin Vaccine Immunol. May. 2011;18(5):807-814.

  24. Holgate ST. Pathogenesis of asthma. Clin Exp Allergy. Jun. 2008;38(6):872-897.

  25. Nguyen KD, Vanichsarn C, Fohner A, Nadeau KC. Selective deregulation in chemokine signaling pathways of CD4+CD25(hi)CD127(lo)/(-) regulatory T cells in human allergic asthma. J Allergy Clin Immunol. Apr. 2009;123(4):933-939.e910.

  26. Pietruczuk M, Eusebio M, Kraszula L, Kupczyk M, Kuna P. Phenotypic characterization of ex vivo CD4+CD25highCD127low immune regulatory T cells in allergic asthma: pathogenesis relevance of their FoxP3, GITR, CTLA-4 and FAS expressions. J Biol Regul Homeost Agents. 2012 Oct-Dec. 2012;26(4):627-639.

  27. Chatila TA. Role of regulatory T cells in human diseases. J Allergy Clin Immunol. Nov. 2005;116(5):949-959;quiz 960.

  28. Shi YH, Shi GC, Wan HY, et al. Coexistence of Th1/Th2 and Th17/Treg imbalances in patients with allergic asthma. Chin Med J (Engl). Jul. 2011;124(13):1951-1956.

  29. Takeda N, Kondo M, Ito S, Ito Y, Shimokata K, Kume H. Role of RhoA inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin. Am J Respir Cell Mol Biol. Dec. 2006;35(6):722-729.

  30. Zeki AA, Franzi L, Last J, Kenyon NJ. Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med. Oct 2009;180(8):731-740.

  31. Ahmad T, Mabalirajan U, Sharma A, et al. Simvastatin improves epithelial dysfunction and airway hyperresponsiveness: from asymmetric dimethyl-arginine to asthma. Am J Respir Cell Mol Biol. Apr. 2011;44(4):531-539.

  32. Group HPSC. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. Jul. 2002;360(9326):7-22.

  33. Endo A. The origin of the statins. 2004. Atheroscler Suppl. Oct. 2004;5(3):125-130.

  34. Sparrow CP, Burton CA, Hernandez M, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol. Jan. 2001;21(1):115-121.

  35. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118.

  36. Profumo E, Buttari B, Saso L, Rigano R. Pleiotropic effects of statins in atherosclerotic disease: focus on the antioxidant activity of atorvastatin. Curr Top Med Chem. 2014;14(22):2542-2551.

  37. Zhang J, Osawa S, Takayanagi Y, et al. Statins directly suppress cytokine production in murine intraepithelial lymphocytes. Cytokine. Feb. 2013;61(2):540-545.

  38. Greenwood J, Walters CE, Pryce G, et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. May. 2003;17(8):905-907.

  39. Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S. Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res. Feb. 2002;45(2):147-154.

  40. Huang KC, Chen CW, Chen JC, Lin WW. Statins induce suppressor of cytokine signaling-3 in macrophages. FEBS Lett. Dec. 2003;555(2):385-389.

  41. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. Jun. 2001;7(6):687-692.

  42. Yilmaz A, Reiss C, Tantawi O, et al. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis. Jan. 2004;172(1):85-93.

  43. Forero-Peña DA, Gutierrez FR. Statins as modulators of regulatory T-cell biology. Mediators Inflamm. 2013;2013:167086.

  44. Jougasaki M, Ichiki T, Takenoshita Y, Setoguchi M. Statins suppress interleukin- 6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. Br J Pharmacol. Mar. 2010;159(6):1294-1303.

  45. Kim YC, Kim KK, Shevach EM. Simvastatin induces Foxp3+ T regulatory cells by modulation of transforming growth factor-beta signal transduction. Immunology. Aug. 2010;130(4):484-493.

  46. Kodach LL, Jacobs RJ, Voorneveld PW, et al. Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway. Gut. Nov. 2011;60(11):1544-1553.

  47. Rodríguez-Perea AL, Montoya CJ, Olek S, Chougnet CA, Velilla PA. Statins Increase the Frequency of Circulating CD4(+)FOXP3(+) Regulatory T Cells in Healthy Individuals. J Immunol Res. 2015;2015:762506.

  48. Xu L, Dong XW, Shen LL, et al. Simvastatin delivery via inhalation attenuates airway inflammation in a murine model of asthma. Int Immunopharmacol . Apr. 2012;12(4):556-564.

  49. Zeki AA, Bratt JM, Rabowsky M, Last JA, Kenyon NJ. Simvastatin inhibits goblet cell hyperplasia and lung arginase in a mouse model of allergic asthma: a novel treatment for airway remodeling? Transl Res. Dec. 2010;156(6):335-349.

  50. Kim DY, Ryu SY, Lim JE, Lee YS, Ro JY. Anti-inflammatory mechanism of simvastatin in mouse allergic asthma model. Eur J Pharmacol. Feb. 2007;557(1):76-86.

  51. Akdis CA. Therapies for allergic inflammation: refining strategies to induce tolerance. Nat Med. May. 2012;18(5):736-749.

  52. Fırıncı F, Karaman M, Cilaker-Mıcılı S, Bagrıyanık A, Uzuner N, Karaman O. The effect of atorvastatin on lung histopathology in a murine model of chronic asthma. Allergol Immunopathol (Madr). 2014;42(4):355-361.

  53. McKay A, Leung BP, McInnes IB, Thomson NC, Liew FY. A novel antiinflammatory role of simvastatin in a murine model of allergic asthma. J Immunol . Mar. 2004;172(5):2903-2908.

  54. Luo FM, Liu CT, Li SQ, Wang ZL. [Simvastatin induces eosinophil apoptosis in vitro]. Zhonghua Jie He He Hu Xi Za Zhi. May. 2005;28(5):320-323.




2020     |     www.medigraphic.com